Skip to main content

Master of Public Health

Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era.

AUTHORS

Oakley F , Desouki MM , Pemmaraju M , Gargano JM , Markowitz LE , Steinau M , Unger ER , Zhu Y , Fadare O , Griffin MR , . American journal of preventive medicine. 2018 5 16; ().
  • NIHMSID: 8704773

ABSTRACT

The 2006 introduction of human papillomavirus vaccine targeted against genotypes 6, 11, 16, and 18 should result in decreased cervical dysplasia in vaccinated women. However, new cervical cancer guidelines to increase screening intervals complicate interpretation of trends. The hypothesis is that cervical dysplasia would decrease only in young vaccine-eligible women, and not older women.

The 2006 introduction of human papillomavirus vaccine targeted against genotypes 6, 11, 16, and 18 should result in decreased cervical dysplasia in vaccinated women. However, new cervical cancer guidelines to increase screening intervals complicate interpretation of trends. The hypothesis is that cervical dysplasia would decrease only in young vaccine-eligible women, and not older women.

Tags: